Why is this trial being carried out?
Some patients with locally advanced pancreatic cancer are considered to have a borderline resectable tumour. This is where the tumour is very close to the major blood vessels that pass under the pancreas or even involves them and therefore it may not be possible to remove the tumour through surgery.
The aim of this study is to determine whether the combination of gemcitabine and nab-paclitaxel (Abraxane®) can shrink a pancreatic cancer that is not felt to be operable enough to enable it to be removed by surgery.
Who is the trial suitable for?
Those patients who have a pancreatic tumour that is not considered to be operable (locally advanced pancreatic cancer) at the time of diagnosis either because the tumour is very close to the major blood vessels that pass under the pancreas or involves them. However doctors consider it may be possible for them to have surgery to remove the tumour if treatment with chemotherapy is able to shrink the tumour.